| Autor: |
Walker, John M., Andrews, Lucy G., Tollefsbol, Trygve O., Tauchi, Tetsuzo, Ohyashiki, Junko H., Ohyashiki, Kazuma |
| Zdroj: |
Telomerase Inhibition; 2008, p181-189, 9p |
| Abstrakt: |
Genetic experiments using a dominant-negative form of human telomerase (DN-hTERT) demonstrated that telomerase inhibition can result in telomeric shortening followed by proliferation arrest and cell death by apoptosis. Neoplastic cells from telomerase RNA null (mTERC−/−) mice showed enhanced chemosensitivity to doxorubicin or related double-strand DNA break (DSB)-inducing agents. Telomerase dysfunction, rather than telomerase inhibition, is proposed to be the principal determinant governing chemosensitivity specifically to DSB-inducing agents. We observed that imatinib and vincristine (VCR), in addition to DSB-inducing agents, also enhanced chemosensitivity in telomestatin-treated K562 cells. This observation suggests that combined use of telomerase inhibitors and imatinib or other chemotherapeutic agents may be a very useful approach to treatment of BCR-ABL-positive leukemia. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
